ACGT is again proud to join an impressive coalition of organizations supporting the national Stand Up to Cancer (SU2C) televised fundraising campaign on Friday, September 5th. Many of ACGT’s Scientific Advisory Council members and Research Fellows are on the research … Read More
Novartis’ CTL019, the immunotherapy treatment that’s seeing tremendous results in achieving remission for leukemia patients, was awarded “breakthrough” status by the FDA, a rare laurel that’s speeding up its review. CTL019 was developed by U. Penn. researcher Dr. Carl June, … Read More
ACGT 2013 Young Investigator Dr. Fan Yang, who is developing new treatments for pediatric brain cancer, is one of six researchers selected for a Faculty Scholar Program Award from the Child Health Research Institute at Stanford, where she is an … Read More
“They took my cancer cells and irradiated them, and then injected them back into my body so my immune system would kick in,” Morrow said. Read More
I am an almost five year survivor of Stage IV NSCLC, adenocarcinoma. I attribute this amazing achievement to the grace of God, aggressive treatment and a “no stone left unturned” attitude. This attitude led me years ago to ACGT and the pioneering work of people like Dr. Jack Roth. Read More
Back in 2004, ACGT provided initial funding for the pioneering gene therapy research of Dr. Carl June of the Abramson Family Cancer Research Institute at the University of Pennsylvania. The research led to a therapy that uses the body’s own T-cells and turns them into weapons aimed directly at cancer. Read More
ACGT is the nation’s only non-profit exclusively dedicated to gene and cell therapies for treating cancer. To date, ACGT has provided over $24 million in grants to top oncologists and funded breakthrough clinical trials that save lives. Learn more about ACGT … Read More
Dr. Michel Sadelain, ACGT Research Fellow, talks about the future of gene therapies for cancer treatment. When/Where: Alliance for Cancer Gene Therapy’s (ACGT) “Achieving Cancer Remission With Cell And Gene Therapies” held October 2013 at the Harvard Club in NYC. … Read More
Dr. Laurence Cooper, ACGT Research Fellow, emphasizes the need for philanthropy and private funding in the fight against cancer. . When/Where: Alliance for Cancer Gene Therapy’s (ACGT) “Achieving Cancer Remission With Cell And Gene Therapies” held October 2013 at the … Read More
The mission of ACGT is to seek out and support revolutionary scientific research into the causes, treatment and prevention of all types of cancer using cells and genes as medicine.
Cell and gene therapies are destroying tumors every day in the laboratory and in human trials, targeting only the cancer with few side effects to healthy tissue. ACGT’s rigorous grant review process, under the guidance of a preeminent Scientific Advisory Council, have resulted in some of the most successful breakthroughs in the history of cancer treatments and led to many patients in complete remission.
100% of our funding supports innovation and translational science that is proving again and again to offer better treatment options than the traditional therapies of chemotherapy, surgery and radiation. Every donation brings us closer to saving lives and changing the way we treat cancer forever.